These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6769315)

  • 1. Management of uterine bleeding by PGs or their synthesis inhibitors.
    Toppozada M; El-Attar A; El-Ayyat MA; Khamis Y
    Adv Prostaglandin Thromboxane Res; 1980; 8():1459-63. PubMed ID: 6769315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of primary dysmenorrhea and dysmenorrhea because of IUP with PG-synthetase inhibitors.
    Dreher E; von Fischer B
    Adv Prostaglandin Thromboxane Res; 1980; 8():1487-93. PubMed ID: 6769316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of IUD-induced bleeding by three non-steroidal anti-inflammatory drugs.
    Toppozada M; Anwar M; Abdel Rahman H; Gaweesh S
    Contracept Deliv Syst; 1982 Apr; 3(2):117-25. PubMed ID: 12338165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IUD-induced uterine bleeding.
    El-badrawi HH; Hafez ES
    Contracept Deliv Syst; 1980 Oct; 1(4):303-18. PubMed ID: 12262133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of prostaglandins in IUD-associated uterine bleeding--effect of a prostaglandin synthetase inhibitor (ibuprofen).
    Roy S; Shaw ST
    Obstet Gynecol; 1981 Jul; 58(1):101-6. PubMed ID: 7243136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ablation, a levonorgestrel-releasing intrauterine device, or hysterectomy.
    Bourdrez P; Bongers MY; Mol BW
    Fertil Steril; 2004 Jul; 82(1):160-6, quiz 265. PubMed ID: 15237006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcium lonazolac and blood loss in users of intrauterine devices. Preliminary report].
    Rubio Lotvin B; Ruíz Moreno JA; González Ansorena R; Ibarrola E; Uranga G; Benítez E
    Ginecol Obstet Mex; 1986 Aug; 54():221-4. PubMed ID: 3781294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin E (alpha tocopherol) in the management of menorrhagia associated with the use of intrauterine contraceptive devices (IUCD).
    Dasgupta PR; Dutta S; Banerjee P; Majumdar S
    Int J Fertil; 1983; 28(1):55-6. PubMed ID: 6134690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment by tranexamic acid in menorrhagia in women using intrauterine devices].
    Bengtsson LP; Weström L
    Lakartidningen; 1971 Aug; 68(33):3685-91. PubMed ID: 5129410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfunctional uterine bleeding.
    Boyd ME
    Can J Surg; 1986 Sep; 29(5):305-7. PubMed ID: 3019496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of epsilon aminocaproic acid in abnormal hemorrhage using intrauterine contraceptive devices].
    Rueda González R
    Rev Colomb Obstet Ginecol; 1969; 20(4):273-8. PubMed ID: 5356119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
    Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
    Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of naproxen on IUD-induced hypermenorrhea.
    Pedron N; Aznar R
    Contracept Deliv Syst; 1983 Jan; 4(1):39-42. PubMed ID: 12264715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study.
    DeVore GR; Owens O; Kase N
    Obstet Gynecol; 1982 Mar; 59(3):285-91. PubMed ID: 6281704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathology of dysfunctional uterine bleeding.
    Sheppard BL
    Clin Obstet Gynaecol; 1984 Apr; 11(1):227-36. PubMed ID: 6370534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should endometrial hyperplasia be regarded as a reason for abnormal uterine bleeding in users of the intrauterine contraceptive device?
    Ozalp S; Kabukcuoglu S; Tanir HM
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):17-20. PubMed ID: 12725671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women.
    Lin X; Gao ES; Li D; Zhang M; Dou LX; Yuan W
    Acta Obstet Gynecol Scand; 2007; 86(9):1126-9. PubMed ID: 17712656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of menstrual blood loss in Brazilian users of the frameless copper-releasing IUD with copper surface area of 330 mm2 and the frameless levonorgestrel-releasing intrauterine system.
    Andrade AT; Souza JP; Andrade GN; Rowe PJ; Wildemeersch D
    Contraception; 2004 Aug; 70(2):173-7. PubMed ID: 15288225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of abnormal bleeding in an intrauterine device user].
    Desmons F; Adam-steen C
    Cah Sexol Clin; 1985; 11(63):185-7. PubMed ID: 12281357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.